It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

CEO Stéphane Bancel on Friday stated that the company is lowering its annual revenue forecast due to the timing of shipments ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

As of March 31, Moderna had $5.97 billion in cash and short-term investments, with total debt of $745 million. But the ...

The biotech company’s revenue halved in 2024, and it continues to face uncertainty in the vaccine market. Biotech giant ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

The Cambridge-based vaccine maker, which became a household name during the pandemic, is cutting its global workforce to ...